Related Experiment Video
Updated: May 27, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis
J W Mandema1, D H Salinger, S W Baumgartner
1Quantitative Solutions, Inc., Menlo Park, California, USA. jmandema@wequantify.com
Abstract:
We present a dose-response meta-analysis to quantify relative efficacy of biologic disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA). There is a strong rationale for this analysis because, although multiple biologics are available, information on head-to-head comparisons is limited. Data on the percentage of patients attaining American College of Rheumatology (ACR) 20, 50, and 70 responses were extracted from 50 randomized controlled trials representing 21,500 patients, five mechanisms of action, and nine biologics. The analysis showed that all tumor necrosis factor inhibitors (anti-TNFs) share the same dose-response relationship for ACR 20, 50, and 70, differing only in potency. Yet there are significant differences in efficacy among the anti-TNFs due to differences in the clinical dose ranges available. At the suggested starting dose, golimumab was the least efficacious, followed by infliximab, adalimumab, etanercept, and certolizumab. Significant differences in the dose-response relationship were found between anti-TNFs and other biologics, resulting in differences in efficacy and differential impact of dose titration.
Related Concept Videos
Dose-Response Relationship: Potency and Efficacy
Dose-Response Relationship: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Measurement of Bioavailability: Pharmacodynamic Methods
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Bioavailability Study Design: Absolute Versus Relative Bioavailability
